Loading organizations...
§ Venture Capital · USA
Venture capital firm investing in breakthrough biomedical technology companies across private equity, public equities, and credit markets.
Catalio Capital Management is a New York City-based venture capital firm that invests in advanced biomedical technology and healthcare companies across private equity, structured opportunities, public equities, and credit markets. The firm manages approximately $2 billion in total assets under management and employs over 40 professionals to support life sciences enterprises at all development stages. Operating alongside a specialized network of more than 45 venture partners, the organization has executed over 100 investments and distributed more than $300 million to its limited partners. Backed by a minority investment from KKR, the firm has built a portfolio featuring notable healthcare and life sciences companies such as COMPASS Pathways, Recursion Pharma, Personal Genome Diagnostics, and Thrive Earlier Detection. Catalio Capital Management was spun out from Camden Partners and officially founded in 2020 by George C. Petrocheilos and R. Jacob Vogelstein.
Key people at Catalio Capital.
Catalio Capital has more than 26 tracked investments across 24 companies. The latest tracked deal is $100.0M Other Equity in Imperative Care in March 2026.
Key people at Catalio Capital.
Catalio Capital Management is a New York-based investment firm specializing in the full lifecycle of innovative healthcare investing, particularly in life sciences and biotechnology. Founded in 2020, it invests across private equity, structured credit, and public equity markets, focusing on breakthrough biomedical technologies and category-defining healthcare companies. Catalio leverages a proprietary network of scientist-entrepreneurs for rigorous scientific due diligence and provides strategic guidance to companies at all stages, from inception to IPO. Its mission centers on supporting transformative healthcare innovations that address unmet medical needs, thereby impacting the startup ecosystem by enabling the growth of pioneering life sciences ventures[1][2][3].
Catalio Capital Management was founded in 2020 in New York City by a team including world-renowned scientist-entrepreneurs and investment professionals. The firm’s leadership includes managing partners and venture partners who are distinguished scientists with proven track records in spinning out and scaling category-defining life sciences companies. This scientific foundation shapes Catalio’s investment philosophy and focus. Over time, the firm has evolved to manage over $1.7 billion in assets and expanded its presence internationally with offices in London and Washington, DC, while maintaining a strong emphasis on biomedical innovation[1][4][5].
Catalio Capital Management rides the wave of rapid innovation in life sciences and biotechnology, a sector driven by advances in biomedical research, diagnostics, drug development, and healthcare data. The timing is critical as breakthroughs in these areas promise to address significant unmet medical needs and transform healthcare delivery globally. Market forces such as increased healthcare spending, aging populations, and technological convergence favor Catalio’s focus. By investing early and across stages, Catalio influences the broader ecosystem by accelerating the commercialization of disruptive healthcare technologies and fostering a network of scientific entrepreneurs who drive innovation forward[1][2][3][4].
Looking ahead, Catalio Capital Management is poised to deepen its impact by continuing to back next-generation life sciences companies that push the boundaries of biomedical innovation. Trends such as precision medicine, gene editing, digital health, and AI-driven drug discovery will likely shape its investment focus. As the life sciences sector grows more complex and capital-intensive, Catalio’s scientific expertise and flexible investment approach will be critical in identifying and nurturing transformative healthcare solutions. Its influence is expected to expand as it helps define the future of healthcare innovation and supports companies that could become the next category leaders in biotech and life sciences[1][3][5].